Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Combine Mirabegron and Solifenacin.

Phase 3Small molecule

MMackay Memorial Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Detrusor OveractivityRecruiting

Detrusor OveractivityPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Detrusor Overactivity

NCT05968885

Clinical

Trials by Indication[1]

Detrusor Overactivity1 trial

Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity

Recruiting·MMackay Memorial Hospital·Phase 4·NCT05968885·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Combine Mirabegron and Solifenacin.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combine Mirabegron and Solifenacin. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combine Mirabegron and Solifenacin.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mackay Memorial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMackay Memorial Hospital

Related News